Considerations for developing an antiarrhythmic agent: a perspective from the pharmaceutical industry.
Antonaccio
M J
MJ
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.
D000889:Anti-Arrhythmia Agents / Q000138:chemical synthesis; D002170:Canada; D004345:Drug Industry; D006801:Humans; D007885:Legislation, Pharmacy
D000889:Anti-Arrhythmia Agents